Nakano Ryuichi, Nakano Akiyo, Abe Michiko, Nagano Noriyuki, Asahara Miwa, Furukawa Taiji, Ono Yasuo, Yano Hisakazu, Okamoto Ryoichi
Department of Microbiology and Infectious Diseases, Nara Medical University, Kashihara, Nara, Japan.
Department of Medical Laboratory Sciences, Kitasato University School of Allied Health Sciences, Sagamihara, Kanagawa, Japan.
Heliyon. 2019 Mar 2;5(3):e01291. doi: 10.1016/j.heliyon.2019.e01291. eCollection 2019 Mar.
Fluoroquinolone (FQ) and cephalosporin (CEP) resistance among Enterobacteriaceae has been increasingly reported. FQ resistance occurs primarily through mutations in DNA gyrase ( and ) and topoisomerase IV ( and ). CEP resistance in Enterobacteriaceae is mainly due to the production of CTX-M type extended-spectrum β-lactamases. Although prevalence and mechanisms of FQ and CEP resistance in Enterobacteriaceae such as have been well studied, little is known about in Japan. In this study, we assessed the prevalence and mechanism of FQ resistance in Japanese clinical isolates of . We collected 5845 isolates from eight hospitals between 2000 and 2013. Prevalence of FQ resistance was calculated as the annual average percentage of all isolates. We selected 50 isolates exhibiting susceptibility, intermediate resistance, or resistance to levofloxacin (LVX) and identified amino acid substitutions in GyrA, GyrB, ParC, and ParE. The prevalence of FQ-resistant gradually increased from 2001 to 2004, reaching 16.6% in 2005, and has remained relatively high (13.3-17.5%) since then. Low-level LVX-resistant strains (MIC, 8-16 mg/L) showed significant changes in GyrB (S464Y or -I, or E466D). High-level LVX-resistant strains (MIC, 32-128 mg/L) displayed significant changes in GyrA (E87K) and ParE (D420N). The highest-level LVX-resistant strains (MIC, ≥ 256 mg/L) presented significant changes in GyrA (E87K or -G), GyrB (S464I or -F), and ParE (D420N). Our findings suggest that substitutions in GyrA (E87) and ParE (D420) have played an important role in the emergence of high-level LVX-resistant isolates (MIC, ≥ 32 mg/L) in Japan.
肠杆菌科细菌对氟喹诺酮(FQ)和头孢菌素(CEP)的耐药性报道日益增多。FQ耐药主要通过DNA促旋酶(gyrA和gyrB)及拓扑异构酶IV(parC和parE)的突变产生。肠杆菌科细菌对CEP的耐药主要归因于CTX-M型超广谱β-内酰胺酶的产生。尽管诸如大肠杆菌等肠杆菌科细菌对FQ和CEP耐药的流行情况及机制已得到充分研究,但在日本对肺炎克雷伯菌的相关情况却知之甚少。在本研究中,我们评估了日本临床分离的肺炎克雷伯菌对FQ的耐药流行情况及机制。我们在2000年至2013年间从八家医院收集了5845株肺炎克雷伯菌分离株。FQ耐药的流行率以所有肺炎克雷伯菌分离株的年度平均百分比计算。我们选择了50株对左氧氟沙星(LVX)表现出敏感、中介耐药或耐药的分离株,并鉴定了GyrA、GyrB、ParC和ParE中的氨基酸替代情况。肺炎克雷伯菌对FQ耐药的流行率从2001年至2004年逐渐上升,2005年达到16.6%,此后一直保持相对较高水平(13.3 - 17.5%)。低水平LVX耐药菌株(MIC,8 - 16 mg/L)在GyrB中出现显著变化(S464Y或 -I,或E466D)。高水平LVX耐药菌株(MIC,32 - 128 mg/L)在GyrA(E87K)和ParE(D420N)中出现显著变化。最高水平LVX耐药菌株(MIC,≥ 256 mg/L)在GyrA(E87K或 -G)、GyrB(S464I或 -F)和ParE(D420N)中出现显著变化。我们的研究结果表明,GyrA(E87)和ParE(D420)中的替代在日本高水平LVX耐药肺炎克雷伯菌分离株(MIC,≥ 32 mg/L)的出现中起了重要作用。